484 related articles for article (PubMed ID: 24140020)
21. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase.
Mori S; Nada S; Kimura H; Tajima S; Takahashi Y; Kitamura A; Oneyama C; Okada M
PLoS One; 2014; 9(2):e88891. PubMed ID: 24558442
[TBL] [Abstract][Full Text] [Related]
22. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance.
Wang RH; Kim HS; Xiao C; Xu X; Gavrilova O; Deng CX
J Clin Invest; 2011 Nov; 121(11):4477-90. PubMed ID: 21965330
[TBL] [Abstract][Full Text] [Related]
23. Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice.
Tripathy S; Jump DB
J Lipid Res; 2013 Jan; 54(1):71-84. PubMed ID: 23099444
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
[TBL] [Abstract][Full Text] [Related]
25. FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway.
Zhou J; Liao W; Yang J; Ma K; Li X; Wang Y; Wang D; Wang L; Zhang Y; Yin Y; Zhao Y; Zhu WG
Autophagy; 2012 Dec; 8(12):1712-23. PubMed ID: 22931788
[TBL] [Abstract][Full Text] [Related]
26. mTORC2 in the center of cancer metabolic reprogramming.
Masui K; Cavenee WK; Mischel PS
Trends Endocrinol Metab; 2014 Jul; 25(7):364-73. PubMed ID: 24856037
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
28. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
29. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
[TBL] [Abstract][Full Text] [Related]
30. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
31. KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc.
Li J; Liu Q; Liu Z; Xia Q; Zhang Z; Zhang R; Gao T; Gu G; Wang Y; Wang D; Chen X; Yang Y; He D; Xin T
J Exp Clin Cancer Res; 2018 Aug; 37(1):194. PubMed ID: 30115078
[TBL] [Abstract][Full Text] [Related]
32. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.
Masui K; Shibata N; Cavenee WK; Mischel PS
Bioessays; 2016 Sep; 38(9):839-44. PubMed ID: 27427440
[TBL] [Abstract][Full Text] [Related]
33. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage.
Han J; Pan XY; Xu Y; Xiao Y; An Y; Tie L; Pan Y; Li XJ
Autophagy; 2012 May; 8(5):812-25. PubMed ID: 22622204
[TBL] [Abstract][Full Text] [Related]
34. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway.
Tan SH; Shui G; Zhou J; Shi Y; Huang J; Xia D; Wenk MR; Shen HM
Autophagy; 2014 Feb; 10(2):226-42. PubMed ID: 24296537
[TBL] [Abstract][Full Text] [Related]
35. POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway.
Yang R; Wang M; Zhang G; Li Y; Wang L; Cui H
Cell Death Dis; 2021 Apr; 12(5):433. PubMed ID: 33931589
[TBL] [Abstract][Full Text] [Related]
36. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
37. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation.
Salazar M; Lorente M; García-Taboada E; Pérez Gómez E; Dávila D; Zúñiga-García P; María Flores J; Rodríguez A; Hegedus Z; Mosén-Ansorena D; Aransay AM; Hernández-Tiedra S; López-Valero I; Quintanilla M; Sánchez C; Iovanna JL; Dusetti N; Guzmán M; Francis SE; Carracedo A; Kiss-Toth E; Velasco G
Cell Death Differ; 2015 Jan; 22(1):131-44. PubMed ID: 25168244
[TBL] [Abstract][Full Text] [Related]
38. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.
Masui K; Cavenee WK; Mischel PS
Brain Pathol; 2015 Nov; 25(6):755-9. PubMed ID: 26526943
[TBL] [Abstract][Full Text] [Related]
39. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Phosphoinositide 3-Kinase/Protein Kinase B Signaling Hampers the Vasopressin-dependent Stimulation of Myogenic Differentiation.
Sorrentino S; Barbiera A; Proietti G; Sica G; Adamo S; Scicchitano BM
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
